Literature DB >> 9298581

1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells.

G G Schwartz1, M H Wang, M Zang, R K Singh, G P Siegal.   

Abstract

1 alpha,25-Dihydroxyvitamin D (1,25 D; also know as calcitriol), the hormonal form of vitamin D, can inhibit the proliferation and promote the differentiation of human prostate adenocarcinoma cells. However, little is known about the effects of 1,25 D on the invasive ability of prostate cancer cells. We used an in vitro bioassay of cell invasion (Amgel assay) to examine the effects of 1,25 D and a "noncalcemic" vitamin D analogue, 1,25-dihydroxy-16-ene-23-yne-cholecalciferol (16-23-D3), on the invasiveness of three well-characterized human prostate carcinoma cell lines: DU 145, PC-3, and LNCaP. PC-3 and LNCaP cells were poorly invasive in Amgel and were hardly affected by treatment with 1,25 D or 16-23-D3 (< 3%). Conversely, DU 145 cells were highly invasive in Amgel, and their invasion was markedly inhibited by 1,25 D and 16-23-D3 (maximally 66 and 59.4% respectively). This effect was both dose-dependent, with maximal inhibition at 1 x 10(-7) M and 72 h. Significant inhibition of invasion was observed at physiological levels of 1,25 D. Neither proliferative indices nor cell cycle kinetics were altered during the experimental exposure. Treatment with 1,25 D and 16-23-D3 caused a selective decrease in the secreted levels of type IV collagenases (MMP-2 and MMP-9). These findings support the hypothesis that 1,25 D reduces the risk of invasive prostate cancer and suggest a role for vitamin D compounds in the chemoprevention of invasive prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9298581

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  35 in total

1.  Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D3 analogs, in-vitro and in-vivo studies.

Authors:  Liron Berkovich; Amnon C Sintov; Shimon Ben-Shabat
Journal:  Invest New Drugs       Date:  2012-06-02       Impact factor: 3.850

2.  Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells.

Authors:  Erik J Tokar; Mukta M Webber
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

3.  Suppression of prostate cancer cell rolling and adhesion to endothelium by 1α,25-dihydroxyvitamin D3.

Authors:  Jong-Wei Hsu; Sayeda Yasmin-Karim; Michael R King; Joel C Wojciechowski; Deanne Mickelsen; Martha L Blair; Huei-Ju Ting; Wen-Lung Ma; Yi-Fen Lee
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 4.  The role of vitamin D in hepatic metastases from colorectal cancer.

Authors:  E Shaw; N Massaro; N T Brockton
Journal:  Clin Transl Oncol       Date:  2017-08-11       Impact factor: 3.405

5.  Vitamin D: a hormone for all seasons--how much is enough?

Authors:  Howard A Morris
Journal:  Clin Biochem Rev       Date:  2005-02

6.  Vitamin D3 modulation of plasminogen activator inhibitor type-1 in human breast carcinomas under organ culture.

Authors:  Edson Mantovani Barbosa; Sueli Nonogaki; Maria Lucia Hirata Katayama; Maria Aparecida Azevedo Koike Folgueira; Venâncio Ferreira Avancini Alves; Maria Mitzi Brentani
Journal:  Virchows Arch       Date:  2003-12-02       Impact factor: 4.064

7.  Characterization of Vitamin D insensitive prostate cancer cells.

Authors:  Adebusola A Alagbala; Michael T Moser; Candace S Johnson; Donald L Trump; Barbara A Foster
Journal:  J Steroid Biochem Mol Biol       Date:  2007-02-05       Impact factor: 4.292

Review 8.  Chemoprevention of carcinoma prostate: a review.

Authors:  M S Ansari; N P Gupta; A K Hemal
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

9.  Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin.

Authors:  Jason Gee; Howard Bailey; Kyungmann Kim; Jill Kolesar; Tom Havighurst; Kendra D Tutsch; William See; Michael B Cohen; Nick Street; Leon Levan; David Jarrard; George Wilding
Journal:  Prostate       Date:  2013-01-17       Impact factor: 4.104

10.  Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC).

Authors:  Ruth C Travis; Francesca L Crowe; Naomi E Allen; Paul N Appleby; Andrew W Roddam; Anne Tjønneland; Anja Olsen; Jakob Linseisen; Rudolf Kaaks; Heiner Boeing; Janine Kröger; Antonia Trichopoulou; Vardis Dilis; Dimitrios Trichopoulos; Paolo Vineis; Domenico Palli; Rosario Tumino; Sabina Sieri; H Bas Bueno-de-Mesquita; Fränzel J B van Duijnhoven; María-Dolores Chirlaque; Aurelio Barricarte; Nerea Larrañaga; Carlos A González; Marcial V Argüelles; Maria-José Sánchez; Pär Stattin; Göran Hallmans; Kay-Tee Khaw; Sheila Bingham; Sabina Rinaldi; Nadia Slimani; Mazda Jenab; Elio Riboli; Timothy J Key
Journal:  Am J Epidemiol       Date:  2009-04-09       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.